These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 34256903)

  • 41. Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner.
    Etxebeste-Mitxeltorena M; Del Rincón-Loza I; Martín-Antonio B
    Front Immunol; 2021; 12():717850. PubMed ID: 34447383
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospects and challenges for use of CAR T cell therapies in solid tumors.
    Ramakrishna S; Barsan V; Mackall C
    Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
    [No Abstract]   [Full Text] [Related]  

  • 43. Adaptive T cell immunotherapy in cancer.
    Ti D; Bai M; Li X; Wei J; Chen D; Wu Z; Wang Y; Han W
    Sci China Life Sci; 2021 Mar; 64(3):363-371. PubMed ID: 32712831
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
    Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
    Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Making CAR T Cells a Solid Option for Solid Tumors.
    Schmidts A; Maus MV
    Front Immunol; 2018; 9():2593. PubMed ID: 30467505
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mechanisms of response and resistance to CAR T cell therapies.
    Berger TR; Maus MV
    Curr Opin Immunol; 2021 Apr; 69():56-64. PubMed ID: 33752101
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming.
    Wang Y; Tong C; Dai H; Wu Z; Han X; Guo Y; Chen D; Wei J; Ti D; Liu Z; Mei Q; Li X; Dong L; Nie J; Zhang Y; Han W
    Nat Commun; 2021 Jan; 12(1):409. PubMed ID: 33462245
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19‑positive malignancies.
    Wang S; Sellner L; Wang L; Sauer T; Neuber B; Gong W; Stock S; Ni M; Yao H; Kleist C; Schmitt A; Müller-Tidow C; Schmitt M; Schubert ML
    Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34165175
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Not Available].
    Le Bourgeois A
    Bull Cancer; 2018 Dec; 105 Suppl 2():S188-S197. PubMed ID: 30686357
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
    Siegler EL; Wang P
    Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors.
    Donnadieu E; Dupré L; Pinho LG; Cotta-de-Almeida V
    J Leukoc Biol; 2020 Oct; 108(4):1067-1079. PubMed ID: 32620049
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CAR T cells: continuation in a revolution of immunotherapy.
    Singh AK; McGuirk JP
    Lancet Oncol; 2020 Mar; 21(3):e168-e178. PubMed ID: 32135120
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chimeric Antigen Receptor (CAR) T-Cell Therapy.
    Pagel JM; West HJ
    JAMA Oncol; 2017 Nov; 3(11):1595. PubMed ID: 28880983
    [No Abstract]   [Full Text] [Related]  

  • 56. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 57. T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies.
    Tang L; Zhang Y; Hu Y; Mei H
    Biomed Res Int; 2021; 2021():6616391. PubMed ID: 33728333
    [TBL] [Abstract][Full Text] [Related]  

  • 58. NR4A transcription factors limit CAR T cell function in solid tumours.
    Chen J; López-Moyado IF; Seo H; Lio CJ; Hempleman LJ; Sekiya T; Yoshimura A; Scott-Browne JP; Rao A
    Nature; 2019 Mar; 567(7749):530-534. PubMed ID: 30814732
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Generation of CAR-T
    Hu J; Liu X
    Int Immunopharmacol; 2024 Jul; 136():112379. PubMed ID: 38833844
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Target selection for CAR-T therapy.
    Wei J; Han X; Bo J; Han W
    J Hematol Oncol; 2019 Jun; 12(1):62. PubMed ID: 31221182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.